- CFO Spotlights
- Profiles
- Jonathan Poole
Profile
Jonathan Poole
Executive Vice President and Chief Financial Officer, Vertex Pharmaceuticals Incorporated
Incoming, effective January 1, 2027. First published here October 28, 2026; built from records as of October 28, 2026.
Jonathan Poole is due to become Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Incorporated on January 1, 2027, according to a filing the company made on September 1, 2026.1
The filing gives Jonathan Poole's previous role as Senior Vice President, Finance at Vertex Pharmaceuticals Incorporated.1 Jonathan Poole already worked at Vertex Pharmaceuticals Incorporated when appointed, so the record counts the move as an internal promotion.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) Pharmaceutical Preparations | Executive Vice President and Chief Financial Officer | Incoming, effective January 1, 2027 |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- January 1, 2027takes effect
Vertex Pharmaceuticals Incorporated appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027. Profile of Charles F. Wagner, Jr..
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”).
[1] Filing by Vertex Pharmaceuticals Incorporated, filed with the SEC on September 1, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Vertex Pharmaceuticals Incorporated. U.S. Securities and Exchange Commission, EDGAR, filed September 1, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Jonathan Poole wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.